Age-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading. Neovascular or "wet" AMD is an advanced form of the disease that can cause rapid and severe vision loss. It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis. Worldwide, around 20 million people are living with wet AMD -- the leading cause of vision loss in people over the age of 60 -- and the condition will affect even more people around the world as the global population ages.
About Uni-Bio Science Group
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com/
About DotBio Pte. Ltd.
DotBio is a highly innovative
biopharmaceutical company with a mission
to harness next-generation antibody technologies to bring more effective
therapies to patients. DotBio takes an innovative therapeutic approach towards the
ideal treatment: the rapid prototyping of multi-functional antibodies to
identify molecules with synergistic activity combinations, optimal architectures
and unique modes of action. DotBio's approach involves the use of its modular
DotBody technology platform, its CoFi and Hot-CoFi stabilization technologies,
high-throughput miniaturized assays and data analytics to generate unique
therapeutic molecules that target both extracellular and intracellular disease
drivers. DotBio is a platform company with a growing portfolio of assets,
including numerous target-specific Dot antibody modules, as well as numerous
pre-clinical assets in the immuno-oncology field. Please visit DotBio's website
for more information: